Long-term outcome of hepatitis C virus infections acquired after pediatric liver transplantation

Liver Transpl. 2011 Dec;17(12):1474-80. doi: 10.1002/lt.22439.

Abstract

The outcomes and characterization of hepatitis C virus (HCV) infections after pediatric liver transplantation (LT) have rarely been reported. We describe our experience with HCV infections after pediatric LT. Ten of 207 children (4.8%) who underwent LT at our institution (1985-2010) developed previously undiagnosed HCV disease. Eight received a liver graft before blood product and donor screening for HCV became available. The mean age at transplantation was 8.9 ± 4.3 years, and the median time from transplantation to the diagnosis of HCV was 15.1 years (range = 0.2-19.7 years). The genotypes were 1 (n = 8), 3 (n = 1), and undetermined (n = 1). At the time of this writing, all the patients were still alive with a mean follow-up of 7.3 ± 5.5 years after the diagnosis of HCV. Five patients did not receive treatment; 2 of these patients achieved spontaneous viral clearance (SVC). Four of the 5 treated patients achieved a sustained virological response, and 3 had an early virological response (EVR). Two of these 4 patients developed chronic rejection while they were on treatment, but this was resolved with a conversion from cyclosporine A to tacrolimus. The remaining patient was continuing treatment and had achieved EVR. In conclusion, despite the limitations of our series, de novo HCV infections after pediatric LT seem to have a slow histological progression. Even with genotype 1, the patients have a good long-term prognosis and respond well to treatment. Nevertheless, chronic rejection during antiviral therapy may develop. In addition, SVC may occur in this population.

MeSH terms

  • Adolescent
  • Antiviral Agents / therapeutic use
  • Biomarkers / blood
  • Child
  • Child, Preschool
  • Chronic Disease
  • Female
  • Graft Rejection / etiology
  • Graft Rejection / prevention & control
  • Hepacivirus / genetics
  • Hepacivirus / immunology
  • Hepatitis C / diagnosis
  • Hepatitis C / drug therapy
  • Hepatitis C / etiology*
  • Hepatitis C / pathology
  • Hepatitis C Antibodies / blood
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Liver Transplantation / adverse effects*
  • Male
  • RNA, Viral / blood
  • Spain
  • Time Factors
  • Treatment Outcome
  • Viral Load

Substances

  • Antiviral Agents
  • Biomarkers
  • Hepatitis C Antibodies
  • Immunosuppressive Agents
  • RNA, Viral